Genetic tests

Full name Analytes Gene panels Disease Laboratory
Hereditary Alpha Tryptasemia TPSAB1 Hereditary Alpha Tryptasemia Centre de Génétique-Institut de Pathologie et de Génétique (IPG)
CYP2C9*2,*3 genotyping - drug metabolism - Pharmacogenetics CYP2C9 Vitamin K antagonists toxicity or dose selection, Oral antidiabetic drugs toxicity or dose selection Centre de Génétique Médicale UCL
Gilbert disease - UGT1A1*28,*36,*37 {A(TA)nTAA} + *6 genotyping - Pharmacogenetics UGT1A1 Transient familial neonatal hyperbilirubinemia, Irinotecan toxicity, Raltegravir toxicity Centre de Génétique Médicale UCL
CYP3A5*3,(*6) genotyping - drug metabolism - Pharmacogenetics CYP3A5 Tacrolimus dose selection Centre de Génétique Médicale UCL
TPMT and NUDT15 sequencing - Pharmacogenetics TPMT, NUDT15 Cisplatin toxicity, Azathioprine or 6-mercatopurine toxicity or dose selection Centre de Génétique Médicale UCL
CYP2D6 genotyping (full gene sequencing + pseudogene and CNV analysis)- drug metabolism - Pharmacogenetics CYP2D6 Codeine toxicity, Resistance to tamoxifene, Antidepressant or antipsychotic toxicity or dose selection Centre de Génétique Médicale UCL
CYP3A4*22 genotyping - drug metabolism - Pharmacogenetics CYP3A4 Tacrolimus dose selection Centre de Génétique Médicale UCL
Vitamin K antagonists toxicity or dose selection - VKORC1 genotyping (-1639G>A + 1173C>T) - Pharmacogenetics VKORC1 Vitamin K antagonists toxicity or dose selection, Prediction of toxicity or dose selection of vitamin K antagonists Centre de Génétique Médicale UCL
Resistance to vitamin K antagonists - VKORC1 sequencing (all exons ) - Pharmacogenetics VKORC1 Resistance to vitamin K antagonists, Prediction of resistance to vitamin K antagonists Centre de Génétique Médicale UCL
SLCO1B1*1b,*5,*15 genotyping (transport protein) - Pharmacogenetics SLCO1B1 Statin toxicity Centre de Génétique Médicale UCL
CYP2C19*2,*3,*17 genotyping - drug metabolism - Pharmacogenetics CYP2C19 Antidepressant or antipsychotic toxicity or dose selection, Resistance to clopidogrel, Voriconazole toxicity Centre de Génétique Médicale UCL
CYP2B6*6,*11,*18 genotyping - drug metabolism - Pharmacogenetics CYP2B6 Efavirenz toxicity Centre de Génétique Médicale UCL
ABCB1 genotyping (c.3435C>T, c.1199G>A ) - Transport protein - Pharmacogenetics ABCB1 Resistance to colchicine Centre de Génétique Médicale UCL
41 pharmacogenes analysis pharmacogenes analysis Centre de Génétique Médicale UCL
MTHFR c.677C>T et c.1298A>C -drug metabolism - Pharmacogenetics MTHFR Centre de Génétique Médicale UCL
TPMT*2,*3A, *3B, *3C, *3D, *4 - drug metabolism - Pharmacogenetics TPMT Centre de Génétique Médicale UCL
Hereditary cancer panel (gene panel) Hereditary Cancer Solution (35 genes) - UCL Centre de Génétique Médicale UCL
CYP3A5*3 genotyping - drug metabolism - Pharmacogenetics CYP3A5 Tacrolimus dose selection Centre de Génétique Humaine - CHU Sart-Tilman
Germline analysis of BRCA1/2 for iPARP treatment BRCA1, BRCA2 Germline analysis of BRCA1/2 for iPARP treatment Hereditary breast cancer Centre de Génétique Humaine - CHU Sart-Tilman
Gilbert disease / Irinotecan sensitivity / Raltegravir toxicity - Pharmacogenetics UGT1A1 Gilbert syndrome (NON RARE IN EUROPE), Irinotecan toxicity Centre de Génétique Humaine - CHU Sart-Tilman
Download XLSX
Download PDF